Cat. No.: HY-15597

Salinomycin

(Synonyms: Procoxacin)

50 Cited Publications

Customer Review

Based on 50 publication(s) in Google Scholar

Salinomycin (Procoxacin), a polyether potassium ionophore antibiotic, selectively inhibits the growth of gram-positive bacteria. Salinomycin is a potent inhibitor of Wnt/β-catenin signaling, blocks Wnt-induced LRP6 phosphorylation. Salinomycin shows selective activity against human cancer stem cells.

For research use only. We do not sell to patients.

Purity: 99.74%
CAS No.: 53003-10-4
Formula: C₄₂H₇₀O₁₁
Molecular Weight:751.00

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Salinomycin Chemical Structure

CAS No.: 53003-10-4

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (50)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target

Coccidia

All Wnt Isoforms :

All Antibiotic Isoforms :

All Parasite Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
2008	IC₅₀	3.2 μM Compound: Salinomycin	Cytotoxicity against human OV2008 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human OV2008 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28651817]
2008	IC₅₀	4.78 μM Compound: Salinomycin	Cytotoxicity against human OV2008 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human OV2008 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 28651817]
2008	IC₅₀	7.44 μM Compound: Salinomycin	Cytotoxicity against human OV2008 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human OV2008 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28651817]
4T1	IC₅₀	3.78 μM Compound: 1	Cytotoxicity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTS assay Cytotoxicity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTS assay	[PMID: 29466777]
4T1	IC₅₀	3.78 μM Compound: 1; SAL	Antiproliferative activity against mouse 4T1 cells by MTT assay Antiproliferative activity against mouse 4T1 cells by MTT assay	[PMID: 30684870]
A2780	IC₅₀	0.16 μM Compound: Sal	Antitumor activity against CD44 negative human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Antitumor activity against CD44 negative human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 39067438]
A-431	IC₅₀	5.27 μM Compound: Sal	Cytotoxicity against human A-431 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay Cytotoxicity against human A-431 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay	[PMID: 39067438]
A549	IC₅₀	3.98 μM Compound: 1	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTS assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTS assay	[PMID: 29466777]
A549	IC₅₀	3.98 μM Compound: 1; SAL	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 30684870]
A549	IC₅₀	25.08 μM Compound: Sal	Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay	[PMID: 39067438]
ACHN	IC₅₀	26.03 μM Compound: Sal	Cytotoxicity against human ACHN cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay Cytotoxicity against human ACHN cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay	[PMID: 39067438]
BALB/3T3	IC₅₀	28.08 μM Compound: 1	Cytotoxicity against mouse BALB/3T3 cells incubated for 72 hrs by MTT assay Cytotoxicity against mouse BALB/3T3 cells incubated for 72 hrs by MTT assay	[PMID: 23079523]
BALB/3T3	IC₅₀	25.8 μM Compound: SAL	Antiproliferative activity mouse BALB/3T3 cells Antiproliferative activity mouse BALB/3T3 cells	[PMID: 24631190]
BALB/3T3	IC₅₀	9.33 μM Compound: SAL	Antiproliferative activity against mouse BALB/3T3 cells assessed as growth inhibition after 72 hrs by SRB method Antiproliferative activity against mouse BALB/3T3 cells assessed as growth inhibition after 72 hrs by SRB method	[PMID: 25644674]
BALB/3T3	IC₅₀	27.76 μM Compound: SAL	Antiproliferative activity against mouse BALB/3T3 cells after 72 hrs Antiproliferative activity against mouse BALB/3T3 cells after 72 hrs	[PMID: 26163197]
BEAS-2B	IC₅₀	13.07 μM Compound: 1	Cytotoxicity against human BEAS2B cells assessed as cell growth inhibition after 48 hrs by MTS assay Cytotoxicity against human BEAS2B cells assessed as cell growth inhibition after 48 hrs by MTS assay	[PMID: 29466777]
BT-474	CC₅₀	14 μM Compound: Salinomycin	Cytotoxicity against human BT474 cells after 48 hrs by MTS assay Cytotoxicity against human BT474 cells after 48 hrs by MTS assay	10.1039/C6MD00328A
Caco-2	IC₅₀	12.99 μM Compound: 1; SAL	Antiproliferative activity against human Caco2 cells by MTT assay Antiproliferative activity against human Caco2 cells by MTT assay	[PMID: 30684870]
Caco-2	IC₅₀	15.67 μM Compound: 4; SAL	Antiproliferative activity against human Caco-2 cells measured after 24 hrs by MTT assay Antiproliferative activity against human Caco-2 cells measured after 24 hrs by MTT assay	[PMID: 38142509]
CAL-27	IC₅₀	30.15 μM Compound: Sal	Cytotoxicity against human CAL-27 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay Cytotoxicity against human CAL-27 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay	[PMID: 39067438]
DU-145	IC₅₀	47.06 μM Compound: Sal	Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay	[PMID: 39067438]
DU-145	CC₅₀	>20 μM Compound: Salinomycin	Cytotoxicity against human DU145 cells after 48 hrs by MTS assay Cytotoxicity against human DU145 cells after 48 hrs by MTS assay	10.1039/C6MD00328A
HCCLM3	IC₅₀	7.99 μM Compound: Sal	Cytotoxicity against human HCCLM3 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay Cytotoxicity against human HCCLM3 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay	[PMID: 39067438]
HEK293	IC₅₀	195 nM Compound: 1	Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 29466777]
HEK293	IC₅₀	329.5 nM Compound: 1	Cytotoxicity against doxycycline inducible T-Rex/K-Ras G12V HEK293 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against doxycycline inducible T-Rex/K-Ras G12V HEK293 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 29466777]
HeLa	IC₅₀	4.49 μM Compound: 1	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTS assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTS assay	[PMID: 29466777]
HeLa	IC₅₀	0.32 μM Compound: 1; SAL	Antiproliferative activity against human HeLa cells by MTT assay Antiproliferative activity against human HeLa cells by MTT assay	[PMID: 30684870]
HeLa	IC₅₀	25.01 μM Compound: Sal	Cytotoxicity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay Cytotoxicity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay	[PMID: 39067438]
Hepatocyte	IC₅₀	0.016 ppm Compound: Salinomycin	Inhibitory activity against second generation merozoids of Eimeria tenella in chick hepatocyte assay in the presence of iproniazid; Value given as 0.08-0.016 Inhibitory activity against second generation merozoids of Eimeria tenella in chick hepatocyte assay in the presence of iproniazid; Value given as 0.08-0.016	[PMID: 9873375]
Hepatocyte	IC₅₀	0.016 ppm Compound: Salinomycin	Inhibitory activity against second generation merozoids of Eimeria tenella in chick hepatocyte assay in the presence of Tranylcypromine; Value given as 0.08-0.016 Inhibitory activity against second generation merozoids of Eimeria tenella in chick hepatocyte assay in the presence of Tranylcypromine; Value given as 0.08-0.016	[PMID: 9873375]
Hepatocyte	IC₅₀	0.016 ppm Compound: Salinomycin	Inhibitory activity against second generation merozoids of Eimeria tenella in chick hepatocyte assay in the absence of inhibitor; Value given as 0.08-0.016 Inhibitory activity against second generation merozoids of Eimeria tenella in chick hepatocyte assay in the absence of inhibitor; Value given as 0.08-0.016	[PMID: 9873375]
Hepatocyte	IC₅₀	0.016p.p.. M Compound: Salinomycin	Inhibitory activity against second generation merozoids of Eimeria tenella in chick hepatocyte assay in the absence of inhibitor; Value given as 0.08-0.016 Inhibitory activity against second generation merozoids of Eimeria tenella in chick hepatocyte assay in the absence of inhibitor; Value given as 0.08-0.016	[PMID: 9873375]
HepG2	IC₅₀	24.5 μM Compound: Salinomycin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 30871771]
HGC-27	IC₅₀	2.57 μM Compound: Sal	Cytotoxicity against human HGC27 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay Cytotoxicity against human HGC27 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay	[PMID: 28262526]
HGC-27	IC₅₀	2.57 μM Compound: 1; SAL	Antiproliferative activity against human HGC27 cells by MTT assay Antiproliferative activity against human HGC27 cells by MTT assay	[PMID: 30684870]
HGC-27	IC₅₀	8.18 μM Compound: 1; SAL	Antiproliferative activity against human HGC27 cells after 48 hrs by MTT assay Antiproliferative activity against human HGC27 cells after 48 hrs by MTT assay	[PMID: 30684870]
HL-60	IC₅₀	0.44 μM Compound: 1	Cytotoxicity against human HL60 cells incubated for 72 hrs by MTT assay Cytotoxicity against human HL60 cells incubated for 72 hrs by MTT assay	[PMID: 23079523]
HL-60	IC₅₀	1.2 μM Compound: SAL	Antiproliferative activity against human HL60 cells Antiproliferative activity against human HL60 cells	[PMID: 24631190]
HL-60	IC₅₀	0.29 μM Compound: SAL	Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 25644674]
HL-60	IC₅₀	0.58 μM Compound: 1	Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTS assay Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTS assay	[PMID: 29466777]
HL-60	GI₅₀	6.63 μM Compound: 1; SAL	Cytotoxicity against human HL60 cells assessed as growth inhibition after 24 hrs by resazurin dye based assay Cytotoxicity against human HL60 cells assessed as growth inhibition after 24 hrs by resazurin dye based assay	[PMID: 30986574]
HL-60	GI₅₀	50.5 μM Compound: SAL	Cytotoxicity against human HL-60 cells by resazurin dye based fluorescence assay Cytotoxicity against human HL-60 cells by resazurin dye based fluorescence assay	[PMID: 33071053]
HL-60	GI₅₀	20 μM Compound: 1; SAL	Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth incubated for 24 hrs and measured at 48 hrs following resazurin challenge by resazurin assay Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth incubated for 24 hrs and measured at 48 hrs following resazurin challenge by resazurin assay	[PMID: 36870272]
HT-29	IC₅₀	1.03 μM Compound: SAL	Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 72 hrs by SRB method Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 72 hrs by SRB method	[PMID: 25644674]
HT-29	IC₅₀	1.43 μM Compound: Sal	Cytotoxicity against human HT-29 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay	[PMID: 28262526]
HT-29	IC₅₀	1.43 μM Compound: 1; SAL	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 28688275]
HT-29	IC₅₀	1.03 μM Compound: 1; SAL	Antiproliferative activity against human HT-29 cells by MTT assay Antiproliferative activity against human HT-29 cells by MTT assay	[PMID: 30684870]
HT-29	IC₅₀	3.21 μM Compound: 1; SAL	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 30684870]
JIMT-1	IC₅₀	0.52 μM Compound: 1	Cytotoxicity against human JIMT1 cells after 72 hrs by MTT assay Cytotoxicity against human JIMT1 cells after 72 hrs by MTT assay	[PMID: 27326340]
JIMT-1	IC₅₀	1.3 μM Compound: 1; SAL	Antiproliferative activity against human JIMT1 cells after 72 hrs by SRB assay Antiproliferative activity against human JIMT1 cells after 72 hrs by SRB assay	[PMID: 30025346]
JIMT-1	IC₅₀	0.52 μM Compound: 1; SAL	Antiproliferative activity against human JIMT1 cells by MTT assay Antiproliferative activity against human JIMT1 cells by MTT assay	[PMID: 30684870]
JIMT-1	IC₅₀	0.52 μM Compound: 1; SAL	Antiproliferative activity against human JIMT1 cells Antiproliferative activity against human JIMT1 cells	[PMID: 30684870]
JIMT-1	IC₅₀	1.3 μM Compound: 1; SAL	Antiproliferative activity against human JIMT1 cells by SRB assay Antiproliferative activity against human JIMT1 cells by SRB assay	[PMID: 30684870]
LoVo	IC₅₀	1.11 μM Compound: 1	Cytotoxicity against human LoVo cells incubated for 72 hrs by MTT assay Cytotoxicity against human LoVo cells incubated for 72 hrs by MTT assay	[PMID: 23079523]
LoVo	IC₅₀	1.5 μM Compound: SAL	Antiproliferative activity against human LoVo cells Antiproliferative activity against human LoVo cells	[PMID: 24631190]
LoVo	IC₅₀	0.36 μM Compound: SAL	Antiproliferative activity against human LoVo cells assessed as growth inhibition after 72 hrs by SRB method Antiproliferative activity against human LoVo cells assessed as growth inhibition after 72 hrs by SRB method	[PMID: 25644674]
LoVo	IC₅₀	0.53 μM Compound: SAL	Antiproliferative activity against human LoVo cells after 72 hrs Antiproliferative activity against human LoVo cells after 72 hrs	[PMID: 26163197]
LoVo	IC₅₀	0.44 μM Compound: 1; SAL	Antiproliferative activity against human LoVo cells after 72 hrs by SRB assay Antiproliferative activity against human LoVo cells after 72 hrs by SRB assay	[PMID: 30025346]
LoVo	IC₅₀	0.44 μM Compound: 1; SAL	Antiproliferative activity against human LoVo cells by SRB assay Antiproliferative activity against human LoVo cells by SRB assay	[PMID: 30684870]
LS180	IC₅₀	0.61 μM Compound: SAL	Antiproliferative activity against human LS180 cells assessed as growth inhibition after 72 hrs by SRB method Antiproliferative activity against human LS180 cells assessed as growth inhibition after 72 hrs by SRB method	[PMID: 25644674]
MCF-10A	IC₅₀	46 μM Compound: 1; SAL	Antiproliferative activity against human MCF10A cells after 72 hrs by SRB assay Antiproliferative activity against human MCF10A cells after 72 hrs by SRB assay	[PMID: 30025346]
MCF-10A	IC₅₀	46 μM Compound: 1; SAL	Antiproliferative activity against human MCF10A cells by SRB assay Antiproliferative activity against human MCF10A cells by SRB assay	[PMID: 30684870]
MCF7	IC₅₀	0.59 μM Compound: 1	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 27326340]
MCF7	IC₅₀	2.98 μM Compound: 1	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 27876192]
MCF7	IC₅₀	9.08 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTS assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTS assay	[PMID: 29466777]
MCF7	IC₅₀	1.5 μM Compound: 1; SAL	Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 30025346]
MCF7	IC₅₀	0.59 μM Compound: 1; SAL	Antiproliferative activity against human MCF7 cells by MTT assay Antiproliferative activity against human MCF7 cells by MTT assay	[PMID: 30684870]
MCF7	IC₅₀	1.5 μM Compound: 1; SAL	Antiproliferative activity against human MCF7 cells by SRB assay Antiproliferative activity against human MCF7 cells by SRB assay	[PMID: 30684870]
MCF7	IC₅₀	9.89 μM Compound: Sal	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay	[PMID: 39067438]
MDA-MB-231	IC₅₀	6.42 μM Compound: 1	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 27876192]
MDA-MB-231	IC₅₀	6.53 μM Compound: Sal	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay	[PMID: 28262526]
MDA-MB-231	IC₅₀	>10 μM Compound: 1; SAL	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 30684870]
MDA-MB-231	IC₅₀	6.42 μM Compound: 1; SAL	Antiproliferative activity against human MDA-MB-231 cells by SRB assay Antiproliferative activity against human MDA-MB-231 cells by SRB assay	[PMID: 30684870]
MDA-MB-231	IC₅₀	6.91 μM Compound: 1; SAL	Antiproliferative activity against human MDA-MB-231 cells by MTT assay Antiproliferative activity against human MDA-MB-231 cells by MTT assay	[PMID: 30684870]
MDA-MB-231	IC₅₀	0.5 μM Compound: 30	Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition by MTS assay Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition by MTS assay	[PMID: 33650861]
MDA-MB-231	IC₅₀	0.9 μM Compound: Sal	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay	[PMID: 39067438]
MDA-MB-231	CC₅₀	>20 μM Compound: Salinomycin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTS assay	10.1039/C6MD00328A
MDCK	CC₅₀	35.6 μM Compound: 80	Cytotoxicity against MDCK cells measured after 3 days by MTT assay Cytotoxicity against MDCK cells measured after 3 days by MTT assay	[PMID: 38330869]
MIA PaCa-2	IC₅₀	5.03 μM Compound: Sal	Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay	[PMID: 39067438]
MIA PaCa-2	CC₅₀	6.5 μM Compound: Salinomycin	Cytotoxicity against human MIAPaCa2 cells after 48 hrs by MTS assay Cytotoxicity against human MIAPaCa2 cells after 48 hrs by MTS assay	10.1039/C6MD00328A
MKN-45	IC₅₀	6.49 μM Compound: Sal	Cytotoxicity against human MKN-45 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay Cytotoxicity against human MKN-45 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay	[PMID: 39067438]
MV4-11	IC₅₀	0.33 μM Compound: SAL	Antiproliferative activity against human MV4-11 cells after 72 hrs Antiproliferative activity against human MV4-11 cells after 72 hrs	[PMID: 26163197]
PC-3	EC₅₀	>1 μM Compound: Salinomycin	Antiproliferative activity against human PC3 cells after 48 hrs Antiproliferative activity against human PC3 cells after 48 hrs	[PMID: 23063400]
SK-BR-3	IC₅₀	0.89 μM Compound: 1; SAL	Antiproliferative activity against human SK-BR-3 cells after 72 hrs by SRB assay Antiproliferative activity against human SK-BR-3 cells after 72 hrs by SRB assay	[PMID: 30025346]
SK-BR-3	IC₅₀	0.89 μM Compound: 1; SAL	Antiproliferative activity against human SKBR3 cells by SRB assay Antiproliferative activity against human SKBR3 cells by SRB assay	[PMID: 30684870]
SK-OV-3	IC₅₀	12.42 μM Compound: Sal	Antitumor activity against CD44 positive human SK-OV-3 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Antitumor activity against CD44 positive human SK-OV-3 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 39067438]
SMMC-7721	IC₅₀	12.04 μM Compound: 1	Cytotoxicity against human SMMC7721 cells assessed as cell growth inhibition after 48 hrs by MTS assay Cytotoxicity against human SMMC7721 cells assessed as cell growth inhibition after 48 hrs by MTS assay	[PMID: 29466777]
SW480	IC₅₀	3.77 μM Compound: 1	Cytotoxicity against human SW480 cells assessed as cell growth inhibition after 48 hrs by MTS assay Cytotoxicity against human SW480 cells assessed as cell growth inhibition after 48 hrs by MTS assay	[PMID: 29466777]
U-87MG ATCC	IC₅₀	38.7 μM Compound: 1; SAL	Antiproliferative activity against human U87 cells by MTT assay Antiproliferative activity against human U87 cells by MTT assay	[PMID: 30684870]
VCaP	EC₅₀	380 nM Compound: Salinomycin	Antiproliferative activity against human VCaP cells Antiproliferative activity against human VCaP cells	[PMID: 23063400]
Vero	CC₅₀	>50 μM Compound: Salinomycin	Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr	10.1101/2020.03.20.999730
Vero	IC₅₀	0.24 μM Compound: Salinomycin	Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr	10.1101/2020.03.20.999730

In Vitro

Salinomycin is a potent inhibitor of the Wnt signaling cascade. Incubation of the malignant lymphocytes with Salinomycin induces apoptosis within 48 h, with a mean IC₅₀ of 230 nM. Salinomycin is also an antibiotic potassium ionophore, has been reported recently to act as a selective breast cancer stem cell inhibitor^[1].
Salinomycin is a novel and an effective anticancer drug, inhibits SW620 cells and Cisp-resistant SW620 cells with IC₅₀ of 1.54±0.23 μM and 0.32±0.05 μM, respectively. Salinomycin is found to have the ability to kill both cancer stem cells (CSCs) and therapy-resistant cancer cells. After continuous Salinomycin treatment for 48 h, the apoptotic cells are observed under the microscope and counted randomly at least 100 cells in one field. The number of apoptotic cells which are stained by Hoechst33342 is significantly increased in Cisp-resistant SW620 cells (20.20±3.72) than that of SW620 cells (9.40±2.07) per 100 cells (p<0.05). After treatment with Salinomycin for 48 h, flow cytometric analysis is used to detect the cell apoptosis both in SW620 cells and Cisp-resistant SW620 cells. The cell apoptotic rate in Cisp-resistant SW620 cells (37.82±3.63%) is significantly higher than that of SW620 cells (16.78±2.56%) (p<0.05)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

After administration of 4 mg/kg Salinomycin (Sal), 8 mg/kg Salinomycin and 10 uL/g saline water for 6 weeks, the mice are sacrificed. The size of the liver tumors in the Salinomycin treatment groups diminishes compare with the control group. The mean diameter of the tumors decreases from 12.17 mm to 3.67 mm (p<0.05) and the mean volume (V=length×width²×0.5) of the tumors decreases from 819 mm³ to 25.25 mm³ (p<0.05). Next, the tumors are harvested, followed by HE staining, immunohistochemistry, and TUNEL assays, to assess the anti-tumor activity of Salinomycin. HE staining shows that the structure of the liver cancer tissue:nuclei of different sizes, hepatic cord structure is destroyed. Immunohistochemistry shows that PCNA expression is lower after Salinomycin treatment. HE staining and TUNEL assays indicates the Salinomycin-treated groups has higher apoptosis rates than control. Furthermore, immunohistochemistry shows an increased Bax/Bcl-2 ratio after Salinomycin treatment. The protein expression of β-catenin decreases in the Salinomycin treatment groups compared with control^[4].
Salinomycin is a kind of monocarboxylic acid polyether type antibiotics, produced by the fermentation of Streptomyces albus, possesses a specific cyclic structure, and can form a complex compound with the pathogenic microorganisms and the extracellular cations of coccidian, especially K⁺, Na⁺, Rb⁺, to alter the intracellular and extracellular ion concentrations^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 53003-10-4
Appearance Solid
Molecular Weight 751.00
Formula C₄₂H₇₀O₁₁
Color White to light yellow
SMILES

[H][C@]1([C@](C)(CC2)O[C@]32[C@H](O)C=C[C@]4(O[C@]([H])([C@@H](CC)C([C@@H](C)[C@@H](O)[C@H](C)[C@]5([H])O[C@]([C@@H](CC)C(O)=O)([H])CC[C@@H]5C)=O)[C@@H](C)C[C@H]4C)O3)CC[C@@](CC)(O)[C@H](C)O1
Synonyms

Procoxacin
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (50)

All WBOthers

Sort by:

Journal Impact Factor

Nat Commun

ATG8ylation-mediated tonoplast invagination mitigates vacuole damage. [Abstract]

2025 Jul 18;16(1):6621. PMID: 40681515

Salinomycin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 18;16(1):6621. [Abstract]

Salinomycin sodium salt (20 μM). The formation of membrane-like structures of GFP-ATG8a in response to three ionophores.
Adv Sci (Weinh)

Targeting Fibrotic Scarring by Mechanoregulation of Il11ra1+/Itga11+ Fibroblast Patterning Promotes Axon Growth after Spinal Cord Injury. [Abstract]

2025 Sep 9:e13476. PMID: 40923460
Adv Sci (Weinh)

A Novel tRF, HCETSR, Derived From tRNA-Glu/TTC, Inhibits HCC Malignancy by Regulating the SPBTN1-catenin Complex Axis. [Abstract]

2025 Feb 8:e2415229. PMID: 39921434
J Control Release

Combined nanomedicines targeting colorectal cancer stem cells and cancer cells. [Abstract]

2020 Oct 10;326:387-395. PMID: 32702392
Biosens Bioelectron

Proximity labeling-assisted click conjugation for electrochemical analysis of specific subpopulations in circulating extracellular vesicles. [Abstract]

2024 Jul 1:255:116245. PMID: 38555770
Pharmacol Res

Cardamonin retards progression of autosomal dominant polycystic kidney disease via inhibiting renal cyst growth and interstitial fibrosis. [Abstract]

2020 May;155:104751. PMID: 32151678
Cell Death Dis

PDIA4 confers resistance to ferroptosis via induction of ATF4/SLC7A11 in renal cell carcinoma. [Abstract]

2023 Mar 11;14(3):193. PMID: 36906674
Acta Biomater

Reversal of epithelial-mesenchymal transition and inhibition of tumor stemness of breast cancer cells through advanced combined chemotherapy. [Abstract]

2022 Oct 15:152:380-392. PMID: 36028199
Cell Commun Signal

M2 macrophages promote myofibroblast differentiation of LR-MSCs and are associated with pulmonary fibrogenesis. [Abstract]

2018 Nov 23;16(1):89. PMID: 30470231

Salinomycin purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2018 Nov 23;16(1):89. [Abstract]

The expression of collagen I, α-smooth muscle actin (α-SMA), and Sca-1 in lung tissues is measured by western blotting in the treatment of Saline, Salinomycin, Bleomycin+Vehicle, and Bleomycin+ Salinomycin.
EMBO Mol Med

A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells. [Abstract]

2019 Oct;11(10):e9930. PMID: 31476112
Chemosphere

PFDA promotes cancer metastasis through macrophage M2 polarization mediated by Wnt/β-catenin signaling. [Abstract]

2024 Jul 3:142758. PMID: 38969224
Cell Rep

Controlling mitochondrial membrane architecture via MIC60 determines viral replication to promote anti-viral immunity. [Abstract]

2025 Jul 22;44(7):115922. PMID: 40628273
Anal Chem

Label-Free Isolation of Low-Adhesion Cells with Stem Properties for Cancer Stem Cell-Specific Drug Evaluation. [Abstract]

2023 Apr 11;95(14):6191. PMID: 36122350
Int J Nanomedicine

Salinomycin-Loaded Small-Molecule Nanoprodrugs Enhance Anticancer Activity in Hepatocellular Carcinoma. [Abstract]

2020 Sep 15;15:6839-6854. PMID: 32982236
Mol Med

The mechanism of enterogenous toxin methylmalonic acid aggravating calcium-phosphorus metabolic disorder in uremic rats by regulating the Wnt/β-catenin pathway. [Abstract]

2025 Jan 22;31(1):19. PMID: 39844078
Cell Biosci

Modaline sulfate promotes Oct4 expression and maintains self-renewal and pluripotency of stem cells through JAK/STAT3 and Wnt signaling pathways. [Abstract]

2021 Aug 4;11(1):156. PMID: 34348786

Salinomycin purchased from MedChemExpress. Usage Cited in: Cell Biosci. 2021 Aug 4;11(1):156. [Abstract]

Salinomycin (0.0078125 μg/ml; for 24 h) reverses the MDLS-induced up-regulation of Oct4. The expression of Oct4 is determined using Western blot analysis.
Talanta

Fluorescence-activated cell sorting-based efficient screening of monensin monoclonal antibodies and applications in lateral flow immunoassay. [Abstract]

2025 Apr 10:293:128128. PMID: 40222095
J Mol Cell Biol

The inwardly rectifying potassium channel KCNJ12 regulates the stemness of hepatocellular carcinoma cells through the Wnt/β-catenin pathway. [Abstract]

2025 Dec 2:mjaf048. PMID: 41328864
Eur J Med Chem

A peptide-salinomycin conjugate with a bystander effect reduces the stemness characteristics of ovarian cancer cells and enhances drug sensitivity. [Abstract]

2024 Oct 5:276:116701. PMID: 39067438
Int J Pharm

Polylactic Acid Based Biodegradable Hybrid Block Copolymeric Nanoparticle Mediated Co-delivery of Salinomycin and Doxorubicin for Cancer Therapy. [Abstract]

2023 Mar 25:635:122779. PMID: 36842520
Nanoscale

Folic acid-targeted redox responsive polylactic acid-based nanoparticles co-delivering pirarubicin and salinomycin suppress breast cancer tumor growth in vivo. [Abstract]

2024 Nov 7;16(43):20131-20146. PMID: 39420738
Int J Mol Sci

The Effect of Cholesterol Efflux on Endothelial Dysfunction Caused by Oxidative Stress. [Abstract]

2023 Mar 21;24(6):5939. PMID: 36983012
Int J Mol Med

Simvastatin promotes endothelial dysfunction by activating the Wnt/β‑catenin pathway under oxidative stress. [Abstract]

2019 Oct;44(4):1289-1298. PMID: 31432100
Int J Mol Sci

Sphingomyelin Synthase 2 Promotes Endothelial Dysfunction by Inducing Endoplasmic Reticulum Stress. [Abstract]

2019 Jun 12;20(12):2861. PMID: 31212751
Cell Oncol (Dordr)

Inhibition of EREG/ErbB/ERK by Astragaloside IV reversed taxol-resistance of non-small cell lung cancer through attenuation of stemness via TGFβ and Hedgehog signal pathway. [Abstract]

2024 Dec;47(6):2201-2215. PMID: 39373858
Eur J Pharmacol

To explore the potential combined treatment strategy for colorectal cancer: Inhibition of cancer stem cells and enhancement of intestinal immune microenvironment. [Abstract]

2025 Jul 5:998:177533. PMID: 40120791
Hepatol Commun

Precision-cut tumor slices for modeling hepatocellular carcinoma enable at-scale drug screening. [Abstract]

2025 May 16;9(6):e0706. PMID: 40377490
RSC Adv

BSA-MnO2-SAL multifunctional nanoparticle-mediated M1 macrophages polarization for glioblastoma therapy. [Abstract]

2021 Nov 2;11(56):35331-35341. PMID: 35493189
Cancers

Physical Cues in the Microenvironment Regulate Stemness-Dependent Homing of Breast Cancer Cells. [Abstract]

2020 Aug 5;12(8):2176. PMID: 32764400
Biomed J

Repurposing old drugs as antiviral agents for coronaviruses. [Abstract]

2020 Aug;43(4):368-374. PMID: 32563698
FASEB J

Stem Cells From the Apical Papilla Cultured in Spheroids Spontaneously Differentiate Into Odontoblasts via N-Cadherin Downregulation. [Abstract]

2025 Dec 31;39(24):e71350. PMID: 41399894
AAPS PharmSciTech

Concomitant Delivery of Pirarubicin and Salinomycin Synergistically Enhanced the Efficacy of Cancer Therapy and Reduced the Risk of Cancer Relapse. [Abstract]

2024 Sep 7;25(7):211. PMID: 39242397
Sci Rep

PFDN2 stabilizes PYCR2 to activate Wnt/β-catenin signaling and promote colorectal cancer progression. [Abstract]

2026 Feb 9;16(1):7909. PMID: 41656306
Oncol Rep

Salinomycin induces apoptosis and differentiation in human acute promyelocytic leukemia cells. [Abstract]

2018 Aug;40(2):877-886. PMID: 29989650

Salinomycin purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2018 Aug;40(2):877-886. [Abstract]

Salinomycin (SAL) has a pro-apoptotic effect on NB4 and HL-60 cells. The apoptosis-related protein levels of Bax and Bcl-2 are assessed by western blotting with the β-actin protein as an internal control.
ACS Infect Dis

Ex Vivo Phenotypic Screening of Two Small Repurposing Drug Collections Identifies Nifuratel as a Potential New Treatment against Visceral and Cutaneous Leishmaniasis. [Abstract]

2021 Aug 13;7(8):2390-2401. PMID: 34114790
Biochim Biophys Acta Mol Cell Res

Salinomycin inhibits SREBP1 to sensitize ferroptosis and ameliorate sorafenib resistance in clear cell renal cell carcinoma. [Abstract]

2025 May 11:119989. PMID: 40360020
Viruses

Ionophore Antibiotics Inhibit Type II Feline Coronavirus Proliferation In Vitro. [Abstract]

2022 Aug 6;14(8):1734. PMID: 36016355
Int J Hyperthermia

Eliminating cancer stem cells can inhibit progression of residual hepatocellular carcinoma after radiofrequency ablation. [Abstract]

2026 Dec;43(1):2643510. PMID: 41883111
J Bioenerg Biomembr

Pre-clinical evidence that salinomycin is active against retinoblastoma via inducing mitochondrial dysfunction, oxidative damage and AMPK activation. [Abstract]

2021 Oct;53(5):513-523. PMID: 34365583
Exp Ther Med

Synthesis of chemical tools to improve water solubility and promote the delivery of salinomycin to cancer cells. [Abstract]

2020 Mar;19(3):1835-1843. PMID: 32104239
Res Sq

2026 Jan 9.
SSRN

2025 Dec 2.
SSRN

2024 Nov 12.
bioRxiv

2024 September 18.
bioRxiv

2024 September 07.
bioRxiv

2023 Jun 25.
bioRxiv

2023 Jan 17.
Research Square Print

2023 Jan 6th.
Norwegian University of Science and Technology

2021 Oct.
bioRxiv

2020 Jun.

Solvent & Solubility

In Vitro:

DMSO : ≥ 36.7 mg/mL (48.87 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.3316 mL

6.6578 mL

13.3156 mL

5 mM

0.2663 mL

1.3316 mL

2.6631 mL

10 mM

0.1332 mL

0.6658 mL

1.3316 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (3.33 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.33 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 3

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline

Solubility: 2.5 mg/mL (3.33 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[2]

For cisplatin or Salinomycin IC₅₀ analysis in SW620 cells or Cisp-resistant SW620 cells, cells (1×10⁴/well) are cultured in 96-well plates and treated with different chemotherapeutics (cisplatin, Salinomycin) in different concentrations for 48 h. Then 20 μL of cell counting kit-8 (CCK-8) is added into each of the 96-wells. After 4 h incubation at 37°C, the optical density (OD) values are detected at 450 nm using the scan reader. Cell growth inhibiting rates are described as cell inhibiting curves and the IC₅₀ parameters (inhibiting concentration of 50% cells) are evaluated by Xlfit 5.2 software. For cell proliferation analysis, SW620 cells or Cisp-resistant SW620 cells (5×10³/well) are also seeded in 96-well plates in serum-containing medium and treated with cisplatin (5 μM, according to the calculated IC50 values of cisplatin in SW620 cells) for 0, 12, 24, 48, 72 and 96 h. Then 20 μL cell counting kit-8 is added into each of the 96-wells. After 4-h incubation at 37°C, the coloring reactions are also quantified at 450 nm^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[3]^[4]

Mice^[3]
Nude mice (nu/nu; 4-6 weeks of age) are used. HepG2 cells are suspended in 100 mL 1:1 serum-free DMEM and Matrigel. Mice are anesthetized with ketamine/xylazine and after surgically opening the abdomen, HepG2 cells are inoculated into the liver parenchyma and mice are monitored every 3 days for 35 days. Finally, 18 nude mice are divided into three groups that are intraperitoneally injected daily for 6 weeks: two Salinomycin-treated groups (4 mg/kg Salinomycin group, 8 mg/kg Salinomycin group) and the control group (saline water group).
Rats^[4]
A total of 10 male rats are used in the experiment. After a routine anesthesia, the abdomen is opened. After a resuspension of high glucose medium not containing serum DMEM, and matrigel, the bladder transitional cancer cell line T24 is inoculated in the parenchyma of bladder in rats, and then the abdomen is sutured. After operation, the rats are randomized into the experiment group and the control group with five in each group. After operation, the rats in the experiment group are immediately given intraperitoneal injection of Salinomycin with a dosage of 8 mg/kg, while the rats in the control group are given intraperitoneal injection of normal saline. A close observation is paid during the drug administration period. After 15 d, the rats are sacrificed by cervical dislocation, and the complete tumor tissues are stripped to observe the tumor growth and metastasis.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (286 KB)
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Portuguese - PT (479 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Lu D, et al. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011 Aug 9;108(32):13253-7. [Content Brief]

[2]. Zhou J, et al. Salinomycin induces apoptosis in cisplatin-resistant colorectal cancer cells by accumulation of reactiveoxygen species. Toxicol Lett. 2013 Oct 24;222(2):139-45. [Content Brief]

[3]. Klose J, et al. Salinomycin: Anti-tumor activity in a pre-clinical colorectal cancer model. PLoS One. 2019 Feb 14;14(2):e0211916. [Content Brief]

[4]. Wang F, et al. Salinomycin Inhibits Proliferation and Induces Apoptosis of Human Hepatocellular Carcinoma Cells In Vitro and In Vivo. PLoS One. 2012; 7(12): e50638. [Content Brief]

[5]. Qu H, et al. Effect of salinomycin on metastasis and invasion of bladder cancer cell line T24. Asian Pac J Trop Med. 2015 Jul;8(7):578-82. [Content Brief]

[6]. Naujokat C, et al. Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol. 2012;2012:950658. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.3316 mL	6.6578 mL	13.3156 mL	33.2889 mL
	5 mM	0.2663 mL	1.3316 mL	2.6631 mL	6.6578 mL
	10 mM	0.1332 mL	0.6658 mL	1.3316 mL	3.3289 mL
	15 mM	0.0888 mL	0.4439 mL	0.8877 mL	2.2193 mL
	20 mM	0.0666 mL	0.3329 mL	0.6658 mL	1.6644 mL
	25 mM	0.0533 mL	0.2663 mL	0.5326 mL	1.3316 mL
	30 mM	0.0444 mL	0.2219 mL	0.4439 mL	1.1096 mL
	40 mM	0.0333 mL	0.1664 mL	0.3329 mL	0.8322 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Salinomycin

Anti-Infection Compound Library

Apoptosis Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Antibacterial Compound Library

Cytoskeleton Compound Library

Antibiotics Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Antiparasitic Compound library

Mitochondria-Targeted Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Antihypertensive Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Extracellular Vesicles (EVs) Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radiosensitizer Library

Mitophagy Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Salinomycin

All Wnt Isoforms

All Antibiotic Isoforms

All Parasite Isoforms

Biological Activity

Chemical Information

Publications (50)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Salinomycin Related Classifications

Cat. No.: HY-15597